Renal Phase 3 Readout Calendar
Industry-sponsored renal trials with primary completion in the next 12 months or last 12 months.
Data last updated July 17, 2026 · source: ClinicalTrials.gov
What you can answer with this page
A confidence-graded calendar of every industry Phase 3 renal trial reading out in the next 12 months — with a per-row staleness flag so you know which completion dates are still credible.
Recently read-out results are free; the upcoming calendar shows a free preview. See the full cross-area calendar → or the Renal landscape →
Recently read out & awaiting topline — Renal
· 3Phase 3 renal trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk Asset: Orforglipron | Type 2 Diabetes +5 | Completed | Q1 2026 2026-03-16 | Completed · awaiting
Updated 3mo ago
| NCT05803421 |
| Bayer | A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease Asset: Finerenone (BAY94-8862) | Non-diabetic Chronic Kidney Disease | Completed | Q4 2025 2025-12-31 | Completed · awaiting
Updated 5mo ago
| NCT05047263 |
| Bayer | A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes Asset: Finerenone | Chronic Kidney Disease +1 | Completed | Q3 2025 2025-08-20 | Completed · awaiting
Updated 9mo ago
| NCT05901831 |
Upcoming renal readouts — next 12 months
· 14Industry Phase 3 renal trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| AMAG Pharmaceuticals, Inc. | A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD) Asset: Ferumoxytol | Chronic Kidney Disease; Iron Deficiency Anemia | Recruiting | Q3 2026 2026-08-31 (est.) | Estimated · fresh
Updated 3mo ago
| NCT03619850 |
| Akebia Therapeutics | To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis Asset: Erythropoiesis-Stimulating Agent (ESA) | Anemia of Chronic Kidney Disease | Active Not Recruiting | Q3 2026 2026-08 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06901505 |
| Kind Pharmaceuticals LLC | A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia Asset: AND017 capsules | Anemia Due to Chronic Kidney Disease | Recruiting | Q4 2026 2026-10-30 (est.) | Estimated · fresh
Updated 4mo ago
| NCT07494409 |
| Ebima Clifford Okundaye | Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression Asset: QRX-3 | Chronic Kidney Diseases +2 | Not Yet Recruiting | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 10mo ago
| NCT06866236 |
| Humacyte, Inc. | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis Asset: Acellular Tissue Engineered Vessel (ATEV) | End Stage Renal Disease (ESRD) | Active Not Recruiting | Q4 2026 2026-10 (est.) | Estimated · stale
Updated 16mo ago
| NCT05908084 |
About this calendar
Dates anchor on the ClinicalTrials.gov primary completion date — the only public, structured signal — and are graded by date type (actual vs sponsor-estimated) and how recently the record was updated. Sponsor-estimated dates can slip silently, so treat each as a current target rather than a guarantee. See the full readout calendar for all areas and filters.